Cargando…

Accounting for treatment use when validating a prognostic model: a simulation study

BACKGROUND: Prognostic models often show poor performance when applied to independent validation data sets. We illustrate how treatment use in a validation set can affect measures of model performance and present the uses and limitations of available analytical methods to account for this using simu...

Descripción completa

Detalles Bibliográficos
Autores principales: Pajouheshnia, Romin, Peelen, Linda M., Moons, Karel G. M., Reitsma, Johannes B., Groenwold, Rolf H. H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513339/
https://www.ncbi.nlm.nih.gov/pubmed/28709404
http://dx.doi.org/10.1186/s12874-017-0375-8
_version_ 1783250639603630080
author Pajouheshnia, Romin
Peelen, Linda M.
Moons, Karel G. M.
Reitsma, Johannes B.
Groenwold, Rolf H. H.
author_facet Pajouheshnia, Romin
Peelen, Linda M.
Moons, Karel G. M.
Reitsma, Johannes B.
Groenwold, Rolf H. H.
author_sort Pajouheshnia, Romin
collection PubMed
description BACKGROUND: Prognostic models often show poor performance when applied to independent validation data sets. We illustrate how treatment use in a validation set can affect measures of model performance and present the uses and limitations of available analytical methods to account for this using simulated data. METHODS: We outline how the use of risk-lowering treatments in a validation set can lead to an apparent overestimation of risk by a prognostic model that was developed in a treatment-naïve cohort to make predictions of risk without treatment. Potential methods to correct for the effects of treatment use when testing or validating a prognostic model are discussed from a theoretical perspective.. Subsequently, we assess, in simulated data sets, the impact of excluding treated individuals and the use of inverse probability weighting (IPW) on the estimated model discrimination (c-index) and calibration (observed:expected ratio and calibration plots) in scenarios with different patterns and effects of treatment use. RESULTS: Ignoring the use of effective treatments in a validation data set leads to poorer model discrimination and calibration than would be observed in the untreated target population for the model. Excluding treated individuals provided correct estimates of model performance only when treatment was randomly allocated, although this reduced the precision of the estimates. IPW followed by exclusion of the treated individuals provided correct estimates of model performance in data sets where treatment use was either random or moderately associated with an individual's risk when the assumptions of IPW were met, but yielded incorrect estimates in the presence of non-positivity or an unobserved confounder. CONCLUSIONS: When validating a prognostic model developed to make predictions of risk without treatment, treatment use in the validation set can bias estimates of the performance of the model in future targeted individuals, and should not be ignored. When treatment use is random, treated individuals can be excluded from the analysis. When treatment use is non-random, IPW followed by the exclusion of treated individuals is recommended, however, this method is sensitive to violations of its assumptions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12874-017-0375-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5513339
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-55133392017-07-19 Accounting for treatment use when validating a prognostic model: a simulation study Pajouheshnia, Romin Peelen, Linda M. Moons, Karel G. M. Reitsma, Johannes B. Groenwold, Rolf H. H. BMC Med Res Methodol Research Article BACKGROUND: Prognostic models often show poor performance when applied to independent validation data sets. We illustrate how treatment use in a validation set can affect measures of model performance and present the uses and limitations of available analytical methods to account for this using simulated data. METHODS: We outline how the use of risk-lowering treatments in a validation set can lead to an apparent overestimation of risk by a prognostic model that was developed in a treatment-naïve cohort to make predictions of risk without treatment. Potential methods to correct for the effects of treatment use when testing or validating a prognostic model are discussed from a theoretical perspective.. Subsequently, we assess, in simulated data sets, the impact of excluding treated individuals and the use of inverse probability weighting (IPW) on the estimated model discrimination (c-index) and calibration (observed:expected ratio and calibration plots) in scenarios with different patterns and effects of treatment use. RESULTS: Ignoring the use of effective treatments in a validation data set leads to poorer model discrimination and calibration than would be observed in the untreated target population for the model. Excluding treated individuals provided correct estimates of model performance only when treatment was randomly allocated, although this reduced the precision of the estimates. IPW followed by exclusion of the treated individuals provided correct estimates of model performance in data sets where treatment use was either random or moderately associated with an individual's risk when the assumptions of IPW were met, but yielded incorrect estimates in the presence of non-positivity or an unobserved confounder. CONCLUSIONS: When validating a prognostic model developed to make predictions of risk without treatment, treatment use in the validation set can bias estimates of the performance of the model in future targeted individuals, and should not be ignored. When treatment use is random, treated individuals can be excluded from the analysis. When treatment use is non-random, IPW followed by the exclusion of treated individuals is recommended, however, this method is sensitive to violations of its assumptions. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12874-017-0375-8) contains supplementary material, which is available to authorized users. BioMed Central 2017-07-14 /pmc/articles/PMC5513339/ /pubmed/28709404 http://dx.doi.org/10.1186/s12874-017-0375-8 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Pajouheshnia, Romin
Peelen, Linda M.
Moons, Karel G. M.
Reitsma, Johannes B.
Groenwold, Rolf H. H.
Accounting for treatment use when validating a prognostic model: a simulation study
title Accounting for treatment use when validating a prognostic model: a simulation study
title_full Accounting for treatment use when validating a prognostic model: a simulation study
title_fullStr Accounting for treatment use when validating a prognostic model: a simulation study
title_full_unstemmed Accounting for treatment use when validating a prognostic model: a simulation study
title_short Accounting for treatment use when validating a prognostic model: a simulation study
title_sort accounting for treatment use when validating a prognostic model: a simulation study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5513339/
https://www.ncbi.nlm.nih.gov/pubmed/28709404
http://dx.doi.org/10.1186/s12874-017-0375-8
work_keys_str_mv AT pajouheshniaromin accountingfortreatmentusewhenvalidatingaprognosticmodelasimulationstudy
AT peelenlindam accountingfortreatmentusewhenvalidatingaprognosticmodelasimulationstudy
AT moonskarelgm accountingfortreatmentusewhenvalidatingaprognosticmodelasimulationstudy
AT reitsmajohannesb accountingfortreatmentusewhenvalidatingaprognosticmodelasimulationstudy
AT groenwoldrolfhh accountingfortreatmentusewhenvalidatingaprognosticmodelasimulationstudy